Everyone is concerned with making money on this investment.

New Post Public Reply Private Reply Replies (2) Message Board
Respert24 Hulk767 #138162
714
Everyone is concerned with making money on this investment. The difference is most everyone else doesn't trot out all the possibilities that could go wrong over and over when given no evidence those possibilities are imminent.

A lot can go wrong, a lot can go right. They've chosen to be silent until they get through the gauntlet of holds, Amarex, and NP. And we've all known that was the strategy. Nothing has changed except the fda decided to walk Cytodyn down an unexpected path, and they currently have us by the short hairs so we had to comply.

That's it. That's all the information we really have.

Nothing there to judge whether anyone on the board or within Cytodyn is competent or incompetent. Or whether the plan they've been executing is a good one or a shite one. Once the hold is lifted and we can learn more about what they've been doing throughout the hold to prepare for the future it'll be much easier to assess that. I choose to be optimistic, or at least not pessimistic, until I have information that lets me come to an informed conclusion. I choose to assume they're executing a common sense strategy that includes a partnership and launching necessary studies as soon as possible, because they've given us no indication they aren't doing that.

But hey, you are entitled to look at and talk about all possibilities, even if your assessment of their silence always reads like it's designed to scare a new investor from jumping in. So with that in mind, I decided to point out a couple you seem to have missed. I’d hate for you to not have a chance to worry publicly about every last negative possibility.

Is anyone concerned that Cyrus being so silent since returning is because he got sick and dipped into the Leronlimab backstock he had access to as the President? Then he lost both legs and his dick fell off because Leronlimab isn't as safe as maybe we thought it was? He gets demoted for his actions but they can't fire him right away because there’s no specific rule against it, then he lawyers up and both sides have to remain quiet for now? I mean, we've always been led to believe that Leronlimab is safe but if people's dicks are falling off and the company refuses to tell us about it I'm going to start worrying. Long and strong though, and I hope Leronlimab saves many lives (and dicks).

Is anyone concerned that the silence out of management might be because the fda contact Cytodyn has been meeting with all this time is possibly not a real employee of the fda at all, but rather a bunch of kids standing on each other’s shoulders and wearing a trenchcoat to pretend they’re an adult? I’m worried that this management team, who has NO EXPERIENCE in vaudeville comedy, are ill prepared to deal with this scenario. It would be a massive setback that I’m not sure we could recover from. Investor for many, many years though, and I pray Leronlimab succeeds.

Is anyone concerned that current management hasn’t told us anything about what they’ll do if they win the Powerball? Most offices I’ve ever been associated with pool their money to buy tickets when the jackpot gets large. It builds comradery, which has been MUCH needed since the NP debacle I correctly predicted. (Long and strong) But yet we hear nothing out of management about it. They can absolutely tell us if they’re buying a group ticket each week and catering in tacos on Tuesdays like any good corporate team would be doing. It doesn’t fall under SEC rules yet all we get is silence. Who’s the weirdo in the office that picks one word every sentence to say in a borderline offensive Mexican accent while eating their taco? They won’t tell us. Who on the board insists the guac has to have raw red onion in it like a psychopath? If these are the people running the company right now and they won’t speak up then I’ll be VERY worried. Show us your losing powerball tickets and receipts from Salsarita’s or I’m going to start worrying. But anyways, long as Ron Jeremy and in it to win it. Hope Leronlimab eradicates cancer for good.

Is anyone concerned about Tanya and her stewardship of the company? All we’ve gotten is silence, and since they haven’t told us exactly what they do every single day I’m starting to worry that maybe she’s a mole. I mean, look at that middle name. Durkee. Sounds foreign. Arab even. I don’t think the fda, an American institution, is going to play nicely with a company run by a possible terrorist who won’t even tell us where they stand on the Israel-Hamas war. Which they absolutely can do because it isn’t under sec rules. So why don’t they say anything? Why don’t the come out and say “hey, we don’t know much about the war going on between Israel and Hamas but we denounce all violence and support a peaceful resolution and also the rumor that Cytodyn’s board is chaired by a sleeper agent is false”. I mean, is that so hard? I’ve been invested in Cytodyn since the 1950’s and that, my friends, is hard. Why can’t the company do something so simple then? But anyways, I have Leronlimab tattooed over six hundred times on my body because I’m so long. Hope it ends all wars.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Brazilian Jiu-Jitsu's Ground Game: Real-World Self-Defense

Updated Category News Views 88

From Mat to Reality: Brazilian Jiu-Jitsu's Claim to Fame It ain't all high kicks and flashy moves when it comes to self-defense, folks. Enter Brazilian Jiu-Jitsu (BJJ)—an art that's not just about show but about practical, gritty reality. Ever been curious why this discipline is hailed for self-defense? Wayne Marble, a seasoned martial arts expert, dishes out the why's...

Continue Reading
Doppel's Strategic Expansion: Adding PropRise Innovators

Updated Category News Views 62

Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...

Continue Reading
Virginia Home Projects: Navigating 2026 Material Costs

Updated Category News Views 63

Penny-Pinching with Pricey Planks: Lumber's Wild Ride Every single time you pick up a hammer, it's like gambling on the money pit that is lumber pricing. These costs are so all over the board in 2026, they make whipping your checkbook out feel like a game of roulette. Folks over in Culpeper and the greater Virginia space are no strangers to this chaotic dance. Travis...

Continue Reading
Fluence Energy Lawsuit: Investors Face Key Deadline

Updated Category News Views 35

Fluence Energy Under Fire Fluence Energy, Inc., ain't having the best of times, folks. If you've been keeping an eye on the stock ticker NASDAQ:FLNC, you probably felt the shiver when the news of a securities fraud class action lawsuit hit the wire. This ain't about some minor slip-up. These allegations are rocking the boat hard. What's at Stake for Investors? Here's the...

Continue Reading
Adient Boosts Buyback, Shields Valuable Tax Assets

Updated Category News Views 47

Adient's Aggressive Buyback and Tax Strategy Well, it looks like Adient's not just sitting on its hands. They've not only opened up the cash taps with a $400 million increase in their share repurchase authorization but also shored up their defenses with a Tax Benefits Preservation Plan. You know, when a company dishes out that kind of cash, it tells you they see some...

Continue Reading
ACLS Expands Fellowship Program for Emerging Scholars

Updated Category News Views 62

Expanding Opportunities in Religious Scholarship Here's something you don't see every day: a program that's actually trying to bridge academia and the practical world. The American Council of Learned Societies (ACLS) is rolling out its second wave of their Graduate Internships on the Spiritual Infrastructure of the Future for 2027, backed by the Templeton Religion Trust....

Continue Reading
Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Updated Category News Views 93

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Continue Reading
Lemon Grove Bans Bird Sales to Combat Cruelty

Updated Category News Views 95

A Bird's Eye View on Lemon Grove's Bold Stand The folks in Lemon Grove, California, just sent out a loud and clear message: put an end to the inhumane sale of birds in pet stores. With 65% of voters backing Measure E, they've decided that birds fly best when they aren't part of a retail circus. Under this new rule, stores can only put birds up for adoption if they're...

Continue Reading
AllianceBernstein Unveils Income-Focused ETF Amid Volatile Times

Updated Category News Views 98

Diving into AllianceBernstein's New Income ETF Well, today we’ve got something stirring in the financial waters over at AllianceBernstein. They’ve launched a new exchange-traded fund (ETF), aptly named the AB Equity Premium Income ETF [INK]. Now, if you’re wondering what’s cooking with this newcomer on the NASDAQ, let’s crack it open and see what’s under the...

Continue Reading
Kate Spade Unveils Festive 2026 Holiday Campaign

Updated Category News Views 49

Kate Spade's Bold Holiday Blitz Ah, holiday campaigns. They’re like the department store windows of the digital age—bursting with color, life, and a hint of commercial frenzy. And Kate Spade New York’s 2026 holiday campaign? Well, it’s certainly making waves. Featuring a crew of high-profile creators, this campaign unfolds like a lavish NYC holiday party—styled...

Continue Reading

Top 5 Most Recently Viewed Articles

Lithium Africa Resources Corp. Expands Board with New Leaders

Updated Category News Views 47

Lithium Africa Resources Corp. Announces Board Changes Lithium Africa Resources Corp. has recently announced notable expansions to its Board of Directors. These strategic enhancements come as the company continues to consolidate its position within the hard rock lithium segment, particularly in various promising regions. New Additions to the Board The Company is excited...

Continue Reading
Transforming Business Interactions with AI-Driven Solutions

Updated Category News Views 128

AI Enhancements in Enterprise Collaboration As artificial intelligence technology evolves, its role in modern business has become more prominent, especially in enhancing collaboration and communication within enterprises. Organizations are increasingly relying on AI capabilities to improve teamwork and customer engagement. The Impact of Conversational AI According to...

Continue Reading
Insights into US Financial 15 Split Corp's Mid-Year Results

Updated Category News Views 121

Financial Overview of US Financial 15 Split Corp The recent financial results released by US Financial 15 Split Corp highlight their performance for the initial half of the fiscal year. Investors and stakeholders are keenly analyzing these results to gauge the company's financial health and operational efficiency. Performance Metrics and Analysis The semi-annual financial...

Continue Reading
Two Promising Utilities Stocks to Watch This Month

Updated Category News Views 78

Investing in Oversold Utilities Stocks The utilities sector has seen some fascinating movements lately, particularly among stocks that may be undervalued and present a unique opportunity for savvy investors. When companies in this sector are trading at lower prices, it can be enticing to consider adding them to your portfolio. An excellent method to gauge potential is...

Continue Reading
Ford Stock's Struggles Highlight Broader Industry Challenges

Updated Category News Views 319

Ford Motor Company's Recent Stock Performance This year has been quite turbulent for the automotive industry, and Ford Motor Company (NYSE: F) recently hit a 52-week low with its stock price falling to $3.33. This marks a dramatic drop, showing a year-long decline of -56.58%. Ford's struggles are not just a reflection of the broader market, but also stem from specific...

Continue Reading